MorphoSys Receives First Patent on Novel Antibody Platform Ylanthia in the US
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Receives First Patent on Novel Antibody Platform Ylanthia in the US
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the
US Patent and Trademark Office (USPTO) has granted the first patent covering the
Company's latest antibody platform Ylanthia, which became commercially available
for existing and new partners in 2012.
"A growing patent portfolio on our new antibody platform Ylanthia is an
important factor for a successful partnering process in our core licensing
markets, which we intend to intensify during the course of 2013", commented Dr.
Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
The new patent (US 8,367,586) covers the composition of MorphoSys's Ylanthia
antibody library. Ylanthia comprises more than 100 billion distinct, fully human
antibodies, which makes it the industry's largest known antibody Fab library. It
uses 36 fixed, naturally-occurring heavy and light chain framework combinations,
which translates into unprecedented structural diversity. The library's
diversity is expected to result in antibodies against previously inaccessible
target molecules and unique epitope coverage.
Ylanthia's antibody frameworks were pre-selected for expression levels,
stability and aggregation behavior. A shift towards higher stability and stress
tolerance will increase shelf life and serum stability of resulting antibody
products, making them more cost-effective to produce and administer. A higher
solubility in turn opens up the path for more convenient ways of administration,
to the benefit of patients. When needed, antibodies from the Ylanthia library
are optimized using MorphoSys's proprietary Slonomics technology. Slonomics
enables optimization of Ylanthia antibodies with unprecedented speed and
flexibility.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1676426/546392.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1676426]
Unternehmensinformation / Kurzprofil:
Datum: 08.02.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 227598
Anzahl Zeichen: 5140
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Receives First Patent on Novel Antibody Platform Ylanthia in the US"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
